DBV Technologies - ADR

NASDAQ:DBVT 3:59:47 PM EDT

10.49

+1.33 (+14.52%)

7:13:49 PM EDT: $10.40 -0.09 (-0.86%)

Market Cap (Intraday)	286.83M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$0.73 Million
Adjusted EPS	-$0.18

See more estimates

10-Day MA	$9.29
50-Day MA	$9.26
200-Day MA	$5.46

See more pivots

DBV Technologies - ADR Stock, NASDAQ:DBVT

177-181, avenue Pierre Brossolette, 107 avenue de la Republique, Chatillon, Hauts-de-France 92320

France

Phone: +33.1.55.42.78.78

Number of Employees: 104

http://www.dbv-technologies.com

Description

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, StÃ?Â©phane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.